Literature DB >> 27121023

Recurrent genetic defects in classical Hodgkin lymphoma cell lines.

S David Hudnall1, Hailong Meng1, Larissa Lozovatsky1, Peining Li2, Matthew Strout3,4, Steven H Kleinstein1,5,6.   

Abstract

Genetic analysis of classical Hodgkin lymphoma (cHL) has been hampered by the paucity of Hodgkin cells in biopsies and their poor growth in vitro. However, a wealth of information has been obtained from cHL cell lines. Here we report results of whole-exome sequencing and karyotypic analysis of five cHL cell lines. Four genes with potentially pathogenic single nucleotide variants (SNV) were detected in three cell lines. SNV were also detected in seventeen HL-related genes and three mitosis-related genes. Copy number variants were detected in four HL-related genes in all five cell lines. Given the high degree of aneuploidy in HL, mitosis-related genes were screened for defects. One mitotic gene (NCAPD2) was amplified in all five HL cell lines, and two genes (FAM190A, PLK4) were amplified in four cell lines. These results suggest that genomic instability of HL may be due to defects in genes involved in chromosome duplication and segregation.

Entities:  

Keywords:  Cytogenetics; Hodgkin lymphoma; genetics; karyotype; whole-exome sequencing

Mesh:

Year:  2016        PMID: 27121023     DOI: 10.1080/10428194.2016.1177179

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Erik Ladewig; Gianluca Schiavoni; Alex Penson; Elisabetta Fortini; Valentina Pettirossi; Yuchun Wang; Ariele Rosseto; Alessandra Venanzi; Sofija Vlasevska; Roberta Pacini; Simonetta Piattoni; Alessia Tabarrini; Alessandra Pucciarini; Barbara Bigerna; Alessia Santi; Alessandro M Gianni; Simonetta Viviani; Antonello Cabras; Stefano Ascani; Barbara Crescenzi; Cristina Mecucci; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  Blood       Date:  2018-04-12       Impact factor: 22.113

2.  PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.

Authors:  Biao Xu; Jingyuan Li; Dehong Xu; Qijie Ran
Journal:  Ir J Med Sci       Date:  2022-05-04       Impact factor: 1.568

Review 3.  PLK4: a promising target for cancer therapy.

Authors:  Yi Zhao; Xin Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-06       Impact factor: 4.553

Review 4.  Non-Coding RNAs in Hodgkin Lymphoma.

Authors:  Anna Cordeiro; Mariano Monzó; Alfons Navarro
Journal:  Int J Mol Sci       Date:  2017-05-29       Impact factor: 5.923

Review 5.  The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers.

Authors:  Sharmila Velapasamy; Christopher W Dawson; Lawrence S Young; Ian C Paterson; Lee Fah Yap
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

6.  Jumping Translocations of 1q in Myelodysplastic Syndrome and Acute Myeloid Leukemia: Report of Three Cases and Review of Literature.

Authors:  T Couture; K Amato; A DiAdamo; P Li
Journal:  Case Rep Genet       Date:  2018-09-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.